
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research PLC's stock has seen an increase of approximately 22%, driven by positive developments regarding its mebufotenin therapies for Treatment-Resistant Depression (TRD), particularly the inhalable candidate GH001, which has shown rapid efficacy and good safety profiles in early stages. Following the FDA's lifting of the clinical hold on GH001, the company is positioned to initiate a global Phase 3 program by 2026, suggesting a strong pathway towards commercialization. Analysts are increasingly optimistic about GH001's long-term sales potential, with estimates projecting over $1.4 billion at peak in TRD alone, bolstered by favorable pricing expectations that align with competitive offerings such as Spravato.
Bears say
GH Research PLC faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential delays in progressing to Phase III trials due to regulatory hurdles and alignment issues with the FDA. Additionally, the company's reliance on the efficacy and safety of its proprietary mebufotenin products in larger clinical studies raises concerns about unforeseen safety signals, as well as the challenges associated with market adoption due to its unique mode of administration compared to competitors. With no revenue-generating products and the inherent difficulties in developing treatments for neuropsychiatric conditions, GH Research's need for ongoing financing compounds the risks related to achieving manufacturing standards, regulatory approval, and successful commercialization in a competitive landscape.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares